Cargando…
In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy
PURPOSE: Imbalance of inhibitory GABAergic neurotransmission has been proposed to play a role in the pathogenesis of temporal lobe epilepsy (TLE). This study aimed to investigate whether [(18)F]-flumazenil ([(18)F]-FMZ) PET could be used to non-invasively characterise GABA(A)/central benzodiazepine...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897736/ https://www.ncbi.nlm.nih.gov/pubmed/24466212 http://dx.doi.org/10.1371/journal.pone.0086722 |
_version_ | 1782300293591990272 |
---|---|
author | Vivash, Lucy Gregoire, Marie-Claude Bouilleret, Viviane Berard, Alexis Wimberley, Catriona Binns, David Roselt, Peter Katsifis, Andrew Myers, Damian E. Hicks, Rodney J. O'Brien, Terence J. Dedeurwaerdere, Stefanie |
author_facet | Vivash, Lucy Gregoire, Marie-Claude Bouilleret, Viviane Berard, Alexis Wimberley, Catriona Binns, David Roselt, Peter Katsifis, Andrew Myers, Damian E. Hicks, Rodney J. O'Brien, Terence J. Dedeurwaerdere, Stefanie |
author_sort | Vivash, Lucy |
collection | PubMed |
description | PURPOSE: Imbalance of inhibitory GABAergic neurotransmission has been proposed to play a role in the pathogenesis of temporal lobe epilepsy (TLE). This study aimed to investigate whether [(18)F]-flumazenil ([(18)F]-FMZ) PET could be used to non-invasively characterise GABA(A)/central benzodiazepine receptor (GABA(A)/cBZR) density and affinity in vivo in the post-kainic acid status epilepticus (SE) model of TLE. METHODS: Dynamic [(18)F]-FMZ -PET scans using a multi-injection protocol were acquired in four male wistar rats for validation of the partial saturation model (PSM). SE was induced in eight male Wistar rats (10 weeks of age) by i.p. injection of kainic acid (7.5–25 mg/kg), while control rats (n = 7) received saline injections. Five weeks post-SE, an anatomic MRI scan was acquired and the following week an [(18)F]-FMZ PET scan (3.6–4.6 nmol). The PET data was co-registered to the MRI and regions of interest drawn on the MRI for selected structures. A PSM was used to derive receptor density and apparent affinity from the [(18)F]-FMZ PET data. KEY FINDINGS: The PSM was found to adequately model [(18)F]-FMZ binding in vivo. There was a significant decrease in hippocampal receptor density in the SE group (p<0.01), accompanied by an increase in apparent affinity (p<0.05) compared to controls. No change in cortical receptor binding was observed. Hippocampal volume reduction and cell loss was only seen in a subset of animals. Histological assessment of hippocampal cell loss was significantly correlated with hippocampal volume measured by MRI (p<0.05), but did not correlate with [(18)F]-FMZ binding. SIGNIFICANCE: Alterations to hippocampal GABA(A)/cBZR density and affinity in the post-kainic acid SE model of TLE are detectable in vivo with [(18)F]-FMZ PET and a PSM. These changes are independent from hippocampal cell and volume loss. [(18)F]-FMZ PET is useful for investigating the role that changes GABA(A)/cBZR density and binding affinity play in the pathogenesis of TLE. |
format | Online Article Text |
id | pubmed-3897736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38977362014-01-24 In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy Vivash, Lucy Gregoire, Marie-Claude Bouilleret, Viviane Berard, Alexis Wimberley, Catriona Binns, David Roselt, Peter Katsifis, Andrew Myers, Damian E. Hicks, Rodney J. O'Brien, Terence J. Dedeurwaerdere, Stefanie PLoS One Research Article PURPOSE: Imbalance of inhibitory GABAergic neurotransmission has been proposed to play a role in the pathogenesis of temporal lobe epilepsy (TLE). This study aimed to investigate whether [(18)F]-flumazenil ([(18)F]-FMZ) PET could be used to non-invasively characterise GABA(A)/central benzodiazepine receptor (GABA(A)/cBZR) density and affinity in vivo in the post-kainic acid status epilepticus (SE) model of TLE. METHODS: Dynamic [(18)F]-FMZ -PET scans using a multi-injection protocol were acquired in four male wistar rats for validation of the partial saturation model (PSM). SE was induced in eight male Wistar rats (10 weeks of age) by i.p. injection of kainic acid (7.5–25 mg/kg), while control rats (n = 7) received saline injections. Five weeks post-SE, an anatomic MRI scan was acquired and the following week an [(18)F]-FMZ PET scan (3.6–4.6 nmol). The PET data was co-registered to the MRI and regions of interest drawn on the MRI for selected structures. A PSM was used to derive receptor density and apparent affinity from the [(18)F]-FMZ PET data. KEY FINDINGS: The PSM was found to adequately model [(18)F]-FMZ binding in vivo. There was a significant decrease in hippocampal receptor density in the SE group (p<0.01), accompanied by an increase in apparent affinity (p<0.05) compared to controls. No change in cortical receptor binding was observed. Hippocampal volume reduction and cell loss was only seen in a subset of animals. Histological assessment of hippocampal cell loss was significantly correlated with hippocampal volume measured by MRI (p<0.05), but did not correlate with [(18)F]-FMZ binding. SIGNIFICANCE: Alterations to hippocampal GABA(A)/cBZR density and affinity in the post-kainic acid SE model of TLE are detectable in vivo with [(18)F]-FMZ PET and a PSM. These changes are independent from hippocampal cell and volume loss. [(18)F]-FMZ PET is useful for investigating the role that changes GABA(A)/cBZR density and binding affinity play in the pathogenesis of TLE. Public Library of Science 2014-01-21 /pmc/articles/PMC3897736/ /pubmed/24466212 http://dx.doi.org/10.1371/journal.pone.0086722 Text en © 2014 Vivash et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Vivash, Lucy Gregoire, Marie-Claude Bouilleret, Viviane Berard, Alexis Wimberley, Catriona Binns, David Roselt, Peter Katsifis, Andrew Myers, Damian E. Hicks, Rodney J. O'Brien, Terence J. Dedeurwaerdere, Stefanie In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy |
title | In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy |
title_full | In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy |
title_fullStr | In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy |
title_full_unstemmed | In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy |
title_short | In Vivo Measurement of Hippocampal GABA(A)/cBZR Density with [(18)F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy |
title_sort | in vivo measurement of hippocampal gaba(a)/cbzr density with [(18)f]-flumazenil pet for the study of disease progression in an animal model of temporal lobe epilepsy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897736/ https://www.ncbi.nlm.nih.gov/pubmed/24466212 http://dx.doi.org/10.1371/journal.pone.0086722 |
work_keys_str_mv | AT vivashlucy invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT gregoiremarieclaude invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT bouilleretviviane invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT berardalexis invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT wimberleycatriona invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT binnsdavid invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT roseltpeter invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT katsifisandrew invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT myersdamiane invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT hicksrodneyj invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT obrienterencej invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy AT dedeurwaerderestefanie invivomeasurementofhippocampalgabaacbzrdensitywith18fflumazenilpetforthestudyofdiseaseprogressioninananimalmodeloftemporallobeepilepsy |